
Nuvalent chases after Nuvation in ROS1 lung cancer
Nuvalent has said it is on course to file for approval of its ROS1 inhibitor zidesamtinib as a lung cancer treatment, although rival Nuvation Bio has beaten it to market. Cambridge, Massachusetts-based Nuvalent has reported the results of its phase 1/2 …